FDA Will Increase Financial Disclosure Requirements For Employees
This article was originally published in The Pink Sheet Daily
Move follows the decision to have center directors vet employees’ consulting arrangements. Agency-wide review of outside activity requests finds no further conflicts beyond a situation at CBER that was questioned by the House Energy & Commerce Committee.
You may also be interested in...
Activities had been approved at lower levels, but the interim policy – issued following questions about behavior of NIH scientists – escalates the oversight. All outside activities by FDA employees will be reviewed as part of the development of a final policy.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.